India to have more than sufficient stock of Liposomal Amphotericin B drug: Mansukh Mandaviya

By Health In Five Writer

India is prepared to have more than sufficient availability of Amphotericin B drug and other drugs which are required to treat patients of Mucormycosis according to Mansukh Mandaviya, Minister of State for Chemicals & Fertilisers, Government of India.

He said, “On 16^th June,2021, active cases of Mucormycosis were 27,142. Even in the future, if cases of Black fungus increases, India is prepared to have more than sufficient availability of Amphotericin B drug and other drugs which are required to treat patients of Mucormycosis. India has increased domestic production remarkably by more than five fold. Domestic production of Liposomal Amphotericin B was just 62,000 vials in April,2021 and now it is expected to cross 3.75 lakh vials in June, 2021. While increasing domestic production, India also placed order to import 9,05,000 Liposomal Amphotericin Bvials through Mylan. India is leaving no stone unturned to boost the availability of  Amphotericin B drugs in the country”.

Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers has allocated a total 7,28,045 vials ofLiposomal Amphotericin B to all the states and Central institutions till 17^th June, 2021. Amphotericin B drug is used for the treatment of Mucormycosis, commonly known as Black Fungus.

State-wise allocation of Liposomal Amphotericin B Vials
from 11^th May, 2021 to 17^th June, 2021

Follow Health In Five on LinkedIn, Facebook, Twitter & Instagram

Subscribe on WhatsApp & Telegram to receive real time updates